New combo therapy shows promise for hard-to-treat lung cancer
NCT ID NCT02823990
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of a cancer vaccine (TG4010) and an immunotherapy drug (nivolumab) in 13 people with advanced non-small cell lung cancer who had already received other treatments. The goal was to see if the combination could shrink tumors or stop them from growing. While the approach aims to boost the immune system to fight cancer, it is not a cure because lung cancer often requires ongoing management.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NON-SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
UCSF Medical Center-Mount Zion
San Francisco, California, 94115, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of California San Diego
San Diego, California, 92103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized cancer care: genetic analysis may unlock targeted treatments for advanced lung cancer
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Genetic roadmaps for advanced cancer: study tests whether expert navigation boosts targeted therapy use
- Could a cancer drug fight the wasting away seen in advanced lung cancer?
- Targeted drug shows promise for Gene-Driven lung cancers
- Gene-Hacked immune cells take on tough cancers